8-K: Amgen Reports Strong Q4 and Full Year 2024 Financial Results, Driven by Volume Growth and Horizon Acquisition

Amgen's Q4 and full year 2024 results showcase robust revenue growth driven by volume increases and the acquisition of Horizon Therapeutics, despite a decrease in GAAP EPS due to mark-to-market losses and higher operating expenses.

Summary

• Amgen announced its financial results for the fourth quarter and full year 2024, demonstrating significant revenue growth.
• Total revenues for the fourth quarter increased by 11% to $9.1 billion, while full-year revenues rose by 19% to $33.4 billion.
• Product sales grew by 11% in Q4 and 19% for the full year, primarily driven by volume growth.
• Excluding the Horizon Therapeutics acquisition, product sales grew by 10% in Q4 and 7% for the full year.
• GAAP earnings per share (EPS) decreased by 18% to $1.16 for Q4 and 39% to $7.56 for the full year, mainly due to mark-to-market losses and higher operating expenses.
• Non-GAAP EPS increased by 13% to $5.31 for Q4 and 6% to $19.84 for the full year, driven by higher revenues.
• The company generated $10.4 billion of free cash flow for the full year, compared to $7.4 billion in 2023.
• Amgen expects total revenues in the range of $34.3 billion to $35.7 billion for the full year 2025.
• GAAP EPS is projected to be between $10.89 and $12.14, while non-GAAP EPS is expected to be in the range of $20.00 to $21.20 for 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, driven by strong revenue growth and pipeline progress. However, the decrease in GAAP EPS and potential risks associated with competition and integration temper the overall sentiment.

Positives

• Robust revenue growth driven by volume increases and the Horizon Therapeutics acquisition.
• Strong performance from key products like Repatha, TEZSPIRE, EVENITY, BLINCYTO, and TAVNEOS, with double-digit sales growth.
• Significant free cash flow generation, reaching $10.4 billion for the full year.
• Positive clinical trial data and regulatory progress for several pipeline programs, including MariTide, TEZSPIRE, and UPLIZNA.
• FDA approval of LUMAKRAS in combination with Vectibix for metastatic colorectal cancer.
• Reduced principal debt outstanding by $4.5 billion for the full year 2024.

Negatives

• Decrease in GAAP EPS due to mark-to-market losses on equity investments and higher operating expenses.
• Decline in sales for established products like EPOGEN, Aranesp, Parsabiv, and Neulasta.
• Expected sales erosion for Prolia and XGEVA due to biosimilar competition in 2025.
• Discontinuation of the SUNRISE Phase 3 study for TEZSPIRE due to limited enrollment.
• Failure of a Phase 2 study of fipaxalparant in patients with diffuse cutaneous systemic sclerosis to meet primary or secondary endpoints.

Risks

• Competition from biosimilars impacting sales of key products.
• Pricing pressure and reimbursement policies affecting product sales.
• Clinical and regulatory setbacks for pipeline programs.
• Manufacturing difficulties or delays.
• Dependence on third-party suppliers and collaborations.
• Potential impacts from global economic conditions and public health threats.
• Failure to successfully integrate the Horizon Therapeutics acquisition.
• Cyberattacks or information security breaches compromising data and systems.

Future Outlook

Amgen expects total revenues in the range of $34.3 billion to $35.7 billion for the full year 2025. GAAP EPS is projected to be between $10.89 and $12.14, while non-GAAP EPS is expected to be in the range of $20.00 to $21.20. Capital expenditures are expected to be approximately $2.3 billion, and share repurchases are not to exceed $500 million.

Management Comments

• Robert A. Bradway, chairman and chief executive officer, stated that robust growth in sales and earnings throughout 2024 reflects the momentum of their business.
• Bradway also mentioned that with strong performance globally, they are investing heavily in their rapidly advancing pipeline to deliver innovative therapies across their four therapeutic areas.

Industry Context

Amgen's focus on volume growth and strategic acquisitions, like Horizon Therapeutics, aligns with the broader industry trend of pharmaceutical companies seeking to expand their product portfolios and revenue streams. The company's emphasis on innovative therapies and pipeline development reflects the industry's ongoing pursuit of novel treatments for various diseases.

Comparison to Industry Standards

• Amgen's revenue growth of 19% for the full year 2024 is competitive compared to other large-cap pharmaceutical companies like Johnson & Johnson and Pfizer, although these companies may have different growth drivers and product portfolios.
• The company's focus on non-GAAP financial measures is a common practice in the pharmaceutical industry to provide investors with a clearer picture of underlying business performance, excluding items like acquisition-related expenses and restructuring costs.
• Amgen's debt leverage ratio of 4.5 times EBITDA is within a reasonable range for a company of its size and financial profile, although it is important to consider the specific terms and conditions of its debt agreements.
• The company's pipeline development efforts, including MariTide and IMDELLTRA, are comparable to other pharmaceutical companies investing in innovative therapies for areas like obesity and cancer.
• Amgen's biosimilar development program aligns with the industry trend of biosimilar competition impacting sales of established products like Enbrel and Prolia.

Stakeholder Impact

• Shareholders: Potential for increased value due to revenue growth and pipeline progress, but also risk due to market volatility and competition.
• Employees: Continued employment opportunities and potential for growth within the company.
• Customers: Access to innovative medicines and therapies.
• Suppliers: Ongoing business relationships and potential for increased demand.
• Creditors: Ability to meet debt obligations and maintain a healthy financial profile.

Next Steps

• Continue Phase 3 development of MariTide with first studies expected to begin in H1 2025.
• Initiate Phase 3 studies of TEZSPIRE in patients with moderate-to-very severe COPD in H1 2025.
• Advance blinatumomab subcutaneous administration to a potentially registration-enabling Phase 2 portion of this study with initiation in H2 2025.
• Complete regulatory submission activities for UPLIZNA in generalized myasthenia gravis (gMG) in H1 2025.
• Present data from the Phase 3 study of Nplate as supportive care in chemotherapy-induced thrombocytopenia in gastrointestinal malignancies at a medical congress in mid-2025.
• Continue regulatory review for TEPEZZA in multiple additional geographies including with the European Medicines Agency (EMA) where approval is anticipated in H2 2025.

Key Dates